ToolGen FY 2025 Annual ReportBeta
ToolGen annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
ToolGen FY 2025 Annual Report Analysis
Business Overview
- • 2025 total revenue KRW 1,306B, 80.5% from patent licensing related to CRISPR gene editing platform
- • Introduced in 2025: Styx-T Platform next-gen CAR-T therapy and GEB-200 treatment for cardiovascular disease with CRISPR-Cas9 LNP delivery
Management Discussion & Analysis
- • Revenue KRW 1.31B (+46.63% YoY), operating loss KRW 23.29B (-6.86%), net loss KRW 36.76B (-689.94%)
- • License income from gene-editing platform patents drove 80.5% of KRW 1.31B total revenue, reflecting patent monetization strategy
Risk Factors
- • No specific quantified foreign exchange risk or sensitivity disclosed
- • No new derivative trades, debt covenants, or regulatory risks explicitly added for FY2025
ToolGen FY 2025 Key Financial MetricsDART
Total Assets
KRW 61.7B
▼ -18.3% YoY
Operating Cash Flow
-KRW 20.2B
▼ -22.9% YoY
CapEx
KRW 451.3M
▲ +3.7% YoY
Source: KIFRS consolidated financial data from ToolGen annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding